Drawing for PLATELETBIO

USPTO serial 90273166

PLATELETBIO

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
—
Examiner
LINERO GUARDA, GERARDO INAKI
Law office
TMO LAW OFFICE 127 - EXAMINING ATTORNEY ASSIGNED

What this means

These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.

Status 602: These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances.

Need help with PLATELETBIO?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Roman Fayerberg

Roman Fayerberg GREENBERG TRAURIG, LLP1 INTERNATIONAL PLACE, SUITE 2000BOSTON, MA 02110UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Platelets that are not bone marrow-derived, platelet variants, megakaryocytes, megakaryocytes variants, and products derived from platelets, megakaryocytes or their variants, and admixtures, namely, extracellular vesicles or exosomes, all the foregoing for medical or clinical use; platelet variants for medical or clinical use; pharmaceutical and drug delivery compositions comprising platelet variants for the treatment of tumors, immune-oncology, hematology, cardiovascular, inflammatory, immune and autoimmune diseases, conditions, or responses, critical care disorders, conditions and injuries, solid organ transplantation, wound healing, neurological disorders and orthopedics; Pharmaceutical compositions for drug delivery comprising non bone marrow-derived platelets, platelet variants for treatment of tumors, immune-oncology, hematology, cardiovascular, inflammatory, immune and autoimmune diseases, conditions, or responses, critical care disorders, conditions and injuries, solid organ transplantation, wound healing, neurological disorders and orthopedics; pharmaceutical compositions comprising platelet variants for transfusion in oncology, trauma and surgery; platelet variants for delivering proteins, antibodies, nucleic acids and other drugs to tumors, sites of vascular injury and inflammation, immune-oncology, hematology, cardiovascular, inflammatory, immune and autoimmune diseases, conditions, or responses, critical care disorders, conditions and injuries, solid organ transplantation, wound healing, neurological disorders and orthopedics; platelet variants for the treatment of tumors, immune-oncology, hematology, cardiovascular, inflammatory, immune and autoimmune diseases, conditions, or responses, critical care disorders, conditions and injuries, solid organ transplantation, wound healing, neurological disorders, and orthopedics; platelet variants as source for growth factors for medical or clinical use; compositions comprising viral vectors for medical or clinical useACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB2): The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.

DateCodeEventWhat it means
Jun 6, 2023MAB2ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPONDThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Jun 5, 2023MAB2ABANDONMENT NOTICE MAILED - FAILURE TO RESPONDThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Jun 5, 2023ABN2ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSEThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Oct 15, 2022GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Oct 15, 2022GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Oct 15, 2022CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 13, 2022TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Apr 13, 2022CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Apr 12, 2022ALIEASSIGNED TO LIE—
Apr 7, 2022ALIEASSIGNED TO LIE—
Apr 6, 2022PARITEAS VOLUNTARY AMENDMENT RECEIVED—
Oct 9, 2021TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Oct 8, 2021CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Oct 8, 2021TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Apr 8, 2021GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 8, 2021GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 8, 2021CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 24, 2021DOCKASSIGNED TO EXAMINER—
Dec 11, 2020NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Oct 27, 2020NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance